Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19

Valneva and Dynavax Technologies Corporation announced their collaboration to initiate a vaccine program for the current coronavirus, COVID-19.

  • Valneva is leveraging its technical and platform capabilities to develop an inactivated, whole virus vaccine candidate against the current coronavirus threat
  • Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the development of Valneva┬┤s COVID-19 vaccine candidate
  • Valneva will seek grant funding to support the required investment for this program

Read more